Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients

Annals of Oncology

Volumn 18, Issue 11, 2007, Pages 1828-1833

  Oudard, Stephane ^a   Banu, E ^a   Scotte, F ^a   Banu, A ^a   Medioni, J ^a   Beuzeboc, P ^b   Joly, F ^c   Ferrero, J M ^d   Goldwasser, F ^e   Andrieu, J M ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b INSTITUT CURIE   (France)

^c François Baclesse Institute   (France)

^d Centre Antoine   (France)

^e Cochin Hospital ^*  (France)

Author keywords

Chemotherapy; Hormone refractory prostate cancer; Overall survival; Predictive factor; Prostate specific antigen doubling time

Indexed keywords

DOCETAXEL; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; COVARIANCE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CONFIDENCE INTERVALS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 36148967358     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm332     Document Type: Article

References (29)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000; 355: 1491-1498.
3. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: A new era begins. CA Cancer J Clin 2005; 55: 300-318; quiz 323-325.
4. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71: 1098-1109.
5. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate ancer. N Engl J Med 2004; 351: 1513-1520.
6. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
7. Oudard S, Banu E, Beuzeboc P et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormorie-refractory prostate cancer. J Clin Oncol 2005; 23: 3343-3351.
8. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
9. Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 516-521.
10. Smaletz O, Scher HI, Small EJ et al. Nomogram for overall survival of patients with progressive metastatc prostate cancer after castration. J Clin Oncol 2002; 20: 3972-3982.
11. Akimoto S, Masai M, Akakura K et al. Tumor marker doubling time in patients with prostate cancer: Determination of prostate-specific antigen and prostatic acid phosphatase doubling time. Eur Urol 1995; 27: 207-212.
12. Collette L, de Reijke TM, Schroder FH. Prostate specific antigen: A prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 2003; 44: 182-189; discussion 189.
13. D'Amico AV, Moul JW, Carroll PR et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95: 1376-1383.
14. Loberg RD, Fielhauer JR, Pienta BA et al. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology 2003; 62: (Suppl 1): 128-133.
15. Schmid HP, Morant R, Bernhard J, Maibach R. Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma. Eur Urol 2003; 43: 28-30.
16. Roberts SG, Blute ML, Bergstralh EJ et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001; 76: 576-581.
17. Svatek RS, Shulman M, Choudhary PK, Benaim E. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 2006; 106: 1047-1053.
18. Fleming TR, Lin DY. Survival analysis in clinical trials: Past developments and future directions. Biometrics 2000; 56: 971-983.
19. Partin AW, Pearson JD, Landis PK et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994; 43: 649-659.
20. Duchesne GM, Millar JL, Moraga V et al. What to do for prostate cancer patients with a rising PSA? - A survey of Australian practice. Int J Radiat Oncol Biol Phys 2003; 55: 986-991.
21. Scher HI, Heller G. Clinical states in prostate cancer: Toward a dynamic model of disease progression. Urology 2000; 55: 323-327.
22. Choo R, DeBoer G, Klotz L et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001; 50: 615-620.
23. Sengupta S, Blute ML, Bagniewski SM et al. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival. J Urol 2006; 175: 1684-1690; discussion 1690.
24. Loberg RD, Fielhauer JR, Pienta BA et al. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology 2003; 62: (Suppl. 1): 128-133.
25. Bidart JM, Thuillier F, Augereau G et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999; 45: 1695-1707.
26. Hanks GE, Hanlon AL, Lee WR et al. Pretreatment prostate-specific antigen doubling times: Clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 1996; 34: 549-553.
27. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999; 281: 1591-1597.
28. Semeniuk RC, Venner PM, North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006; 68: 565-569.
29. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 1989; 8: 431-440.